[ad_1]
 |
What’s new: The maker of one of China’s first potential Covid-19 vaccines is recruiting patients for its second phase of human trials, developer CanSino Biologics Inc. (CanSinoBIO) said Thursday.
The head of the Hong Kong-listed vaccine manufacturer, Yu Xuefeng, He said The phase 1 trial, conducted on a small number of healthy people to determine if the substance is harmful, was ongoing, but had given early indications that the vaccine was safe enough to progress.
The Phase 2 trial was expected to start “soon” and needed 500 healthy adult volunteers.
Background: Jointly developed by CanSinoBIO and the Institute of Biotechnology of the Chinese Academy of Military Medical Sciences, “Ad5-nCoV” is a genetic engineering vaccine candidate delivered by an adenovirus.
Started a phase 1 trial in March, and records show That trial is expected to conclude in December.
Ad5-nCoV is one of several vaccines developed by researchers around the world, some of which are already being tested in people.
Despite promising initial progress, getting any Covid-19 vaccine candidate to go through all clinical trials and mass production could take 18 months or more, the experts say.
Quick Takes are condensed versions of stories related to China for quick news that you can use. To read Caixin’s full article in Chinese, click here.
Related: Chinese vaccine approved for human testing at virus epicenter
Contact journalist Guo Yingzhe ([email protected]) and editor Flynn Murphy ([email protected])
Sign up to read this article for free.
Check in
